John Maxwell joined Tango Therapeutics from Vertex Pharmaceuticals, where he spent 15 years in roles of increasing responsibility in the Medicinal Chemistry group. Most recently, John led a group with primary responsibilities for projects in early research, lead generation and lead optimization. He has worked in a variety of therapeutic areas and took on the role of chemistry head in infectious disease and oncology projects and research project leader in oncology and respiratory disease projects. His teams have delivered clinical candidates on projects including Hepatitis C protease and DNA-PK for oncology.
John received his doctorate in chemistry from Johns Hopkins University and obtained a Bachelor of Science in chemistry from St. Joseph’s University.